mani
pathogen
relev
human
diseas
infect
anim
speci
therefor
anim
model
reconstitut
harbour
human
tissu
explor
host
review
summar
recent
advanc
util
mice
human
immun
system
compon
reconstitut
hematopoiet
progenitor
cell
vivo
mice
use
studi
human
pathogen
replic
leucocyt
addit
studi
replic
pathogen
reconstitut
human
immun
system
compon
also
analyz
initi
immun
respons
control
infect
moreov
new
anim
model
human
infecti
diseas
replic
reactiv
human
immun
system
vaccin
candid
especi
adjuv
contain
faith
mice
prefer
model
speci
immunolog
research
howev
million
year
diverg
evolut
mous
man
accumul
mani
differ
among
organ
differ
fall
olfact
reproduct
immun
system
mani
differ
immun
system
relat
innat
immun
ensur
surviv
individu
first
day
infect
adapt
immun
respons
tailor
specif
need
particular
challeng
sinc
mice
men
encount
virtual
nonoverlap
group
pathogen
due
occup
differ
ecolog
nich
shape
innat
immun
system
two
speci
quit
differ
differ
becom
especi
import
innat
immun
system
initi
rapid
adapt
immun
respons
therefor
human
immun
system
reactiv
toward
vaccin
pathogen
human
diseas
caus
condit
gener
difficult
model
mice
instanc
studi
human
immun
cell
ideal
vivo
would
prefer
purpos
investig
transfer
human
immun
cell
immun
compromis
mice
sinc
late
order
overcom
limit
vitro
cultur
system
human
leucocyt
howev
advent
cytokin
receptor
common
gamma
chain
c
knockout
mice
alreadi
lack
b
cell
due
scid
mutat
recombinas
rag
defici
becom
possibl
engraft
signific
frequenc
cell
human
immun
compart
transfer
fetal
neonat
human
hematopoet
progenitor
cell
hpc
mice
mice
enhanc
engraft
gener
attribut
lack
xenoreact
mediat
mous
natur
killer
nk
cell
seem
origin
loss
signal
accordingli
nodscid
c
balbc
c
mice
often
use
human
immun
compart
reconstitut
transplant
hpc
even
studi
use
parallel
transplant
human
fetal
liver
fetal
thymu
hpc
nodscid
mice
blt
altern
figur
mice
transplant
human
hpc
abl
reconstitut
human
mononuclear
cell
peripher
blood
spleen
sizabl
compart
human
b
cell
cell
nk
cell
monocytemacrophag
dendrit
cell
dc
three
month
hpc
transfer
tabl
review
summar
studi
immunocompet
reconstitut
human
immun
system
compon
discuss
use
studi
infect
human
pathogen
well
vaccin
approach
immun
respons
start
activ
innat
immun
system
also
harbor
extens
genet
differ
mous
man
therefor
reconstitut
function
capac
innat
human
immun
compart
hpctransplant
mice
need
analyz
detail
order
determin
reconstitut
immun
cell
serv
surrog
human
innat
immun
cell
studi
vaccin
infect
one
extens
studi
cell
popul
human
innat
immun
system
mice
reconstitut
human
immun
system
compon
nk
cell
lineag
initi
studi
mainli
reli
vivo
applic
human
cytokin
growth
factor
variou
combin
achiev
sustain
human
nk
cell
develop
expans
cell
detect
level
follow
summar
publish
data
develop
tissu
distribut
frequenc
phenotyp
function
human
nk
cell
reconstitut
mice
one
first
studi
specif
address
human
nk
cell
develop
vivo
use
adult
nodscid
mice
week
age
transplant
hpc
cord
blood
without
treatment
nk
cell
could
detect
model
howev
repetit
treatment
variou
cytokinegrowth
factor
combin
lead
transient
increas
nk
cell
within
reconstitut
mice
last
week
note
cytokin
combin
led
develop
human
nk
cell
vivo
contain
ligand
human
nk
cell
frequenc
frequenc
cell
among
human
lymphocyt
could
achiev
bone
marrow
spleen
even
higher
percentag
peripher
blood
nkt
cell
popul
induc
upon
treatment
cell
report
phenotyp
nk
cell
found
studi
mostli
dim
kirwith
express
nk
cell
nk
cell
isol
bone
marrow
cytokin
treat
mice
produc
addit
vitro
stimul
albeit
much
lower
frequenc
compar
equal
stimul
nk
cell
human
peripher
blood
interestingli
vitro
expand
nk
cell
isol
reconstitut
mice
adopt
transfer
nonreconstitut
nodscid
recipi
challeng
tumor
cell
signific
decreas
tumor
burden
observ
cell
line
mhci
defici
erythroleukem
cell
line
studi
suggest
function
human
nk
cell
reconstitut
mice
requir
addit
activ
cytokin
maintain
function
contrast
hpc
isol
human
fetal
liver
transfer
intrahepat
newborn
balbc
c
instead
adult
nodscid
mice
anoth
report
could
show
multilineag
reconstitut
human
immun
cell
absolut
number
cell
spleen
around
develop
human
nk
cell
low
frequenc
human
lymphocyt
organ
analyz
human
nk
cell
could
divid
two
main
subset
present
human
bright
kirand
dim
kir
nk
cell
latter
irrespect
local
repres
major
howev
contrast
distribut
two
subset
man
remark
differ
subset
ratio
differ
organ
interest
nk
cell
almost
devoid
express
could
also
detect
cell
nk
cell
origin
express
nk
cell
specif
marker
well
kir
human
nk
cell
compart
model
function
secret
stimul
ex
vivo
degranul
respons
cocultur
nk
cell
suscept
erythroleukemia
cell
line
presenc
could
detect
direct
comparison
nk
cell
effector
function
observ
human
sampl
provid
author
studi
furthermor
report
expans
human
nk
cell
compart
shortli
repeat
administr
hybrid
molecul
happen
expens
skew
toward
differenti
dim
phenotyp
convert
nearli
nk
cell
popul
accompani
acquisit
kir
express
durat
increas
nk
cell
frequenc
treatment
report
along
line
two
studi
compar
nk
cell
reconstitut
balbc
c
mice
neonat
inject
cord
blood
cell
reconstitut
compart
upon
hpc
transfer
nodscid
c
mice
latter
cell
develop
occur
reconstitut
balbc
c
mice
highest
frequenc
cell
detect
lymph
node
major
cell
also
express
cell
marker
analysi
nk
cell
show
nk
cell
lymph
node
virtual
devoid
express
spleen
nk
cell
blood
nk
cell
express
administr
adenovir
vector
encod
human
led
express
kir
almost
splenic
nk
cell
signific
increas
frequenc
cell
spleen
around
cell
administr
data
suggest
signific
nk
cell
frequenc
achiev
hpc
transfer
balbc
c
mice
addit
supplement
termin
differenti
nk
cell
bright
nk
cell
achiev
applic
cytokin
nodscid
c
mice
reconstitut
cord
blood
cell
inject
intracardi
newborn
show
higher
constitut
level
nk
cell
reconstitut
expans
nk
cell
blood
spleen
bone
marrow
liver
lung
similar
mention
report
chen
et
al
hydrodynam
inject
plasmid
encod
human
ligand
frequenc
nk
cell
among
human
cell
detect
one
week
gene
deliveri
steadi
declin
still
elev
level
observ
period
day
nine
day
hydrodynam
inject
ligand
encod
plasmid
absolut
nk
cell
number
per
spleen
high
note
administr
ligand
encod
plasmid
led
overal
increas
cell
content
spleen
bone
marrow
concomit
increas
dc
monocytemacrophag
b
cell
cell
number
appar
cytokineinduc
nk
cell
expans
occur
expens
loss
immatur
kirphenotyp
major
nk
cell
bone
marrow
spleen
express
kir
molecul
howev
direct
comparison
nk
cell
compart
reconstitut
nsg
mice
without
treatment
conduct
nk
cell
isol
bone
marrow
spleen
reconstitut
nsg
mice
treat
cytokineencod
plasmid
abl
specif
lyse
tumor
cell
vitro
produc
presenc
poli
c
autolog
human
dendrit
cell
dc
level
also
increas
sera
cytokin
treat
mice
vivo
poli
c
stimul
moreov
hydrodynam
inject
dna
plasmid
encod
gmcsf
ligand
combin
well
mcsf
combin
epo
led
distinct
increas
frequenc
dendrit
cell
monocytesmacrophag
human
erythrocyt
recent
group
report
robust
stabl
overal
nk
cell
reconstitut
nodscid
c
mice
neonat
reconstitut
human
fetal
liver
hpc
intrahepat
inject
model
allow
multilineag
reconstitut
frequenc
peripher
blood
nk
cell
number
spleen
averag
cell
frequenc
rang
peripher
blood
mice
nk
cell
repres
averag
human
lymphocyt
nk
cell
detect
organ
analyz
lowest
frequenc
bone
marrow
analysi
human
nk
cell
compart
demonstr
develop
nk
cell
subset
present
human
cord
blood
interestingli
nk
cell
subset
found
also
exist
human
cord
blood
present
low
frequenc
human
adult
blood
subset
upregul
express
vivo
transfer
autolog
reconstitut
nsg
mice
well
vitro
presenc
comparison
pbmc
deriv
nk
cell
decreas
function
capac
nk
cell
mice
human
immun
system
compon
cord
blood
detect
deficit
mainli
confin
dim
nk
cell
subset
importantli
preactiv
human
nk
cell
compart
reconstitut
mice
human
cord
blood
vitro
poli
c
vivo
render
nk
cell
capabl
secret
degranul
respons
target
cell
line
level
activ
similar
human
adult
peripher
blood
nk
cell
addit
preactiv
poli
c
vivo
led
enhanc
kill
mhcclass
neg
tumor
cell
compar
parent
mhcclass
express
tumor
cell
studi
demonstr
function
compet
nk
cell
reconstitut
half
human
physiolog
frequenc
neonat
hpc
transfer
newborn
nodscid
c
mice
cellular
frequenc
expand
activ
contrast
recent
report
describ
adult
nodscid
c
mice
transplant
mobil
cell
human
peripher
blood
donor
treat
continu
stabil
develop
nk
cell
system
report
function
inert
lack
cytotox
activ
target
cell
secret
bulk
splenocyt
cultur
pma
ionomycin
stimul
phenotyp
cell
bright
mostli
kir
frequenc
nk
cell
compart
studi
exceed
organ
analyz
data
indic
neonat
transplant
fetal
hpc
might
superior
reconstitut
function
nk
cell
compart
immun
compromis
mice
final
blt
mice
nodscid
mice
transplant
adult
human
thymu
liver
organoid
kidney
capsul
follow
transfer
human
fetal
liver
cell
reconstitut
human
nk
cell
compart
also
independ
addit
cytokin
reach
level
cell
peripher
blood
week
transplant
detail
analysi
nk
cell
phenotyp
function
capac
model
howev
report
date
summari
high
reconstitut
effici
hpc
inject
nodscid
c
mice
blt
mice
compar
mous
model
presenc
therein
function
compet
rest
nk
cell
compart
suggest
preferenti
use
model
analysi
role
human
nk
cell
innat
immun
respons
infect
cancer
function
data
innat
immun
respons
mediat
myeloid
compart
mous
model
reconstitut
human
immun
system
compart
scarc
due
fact
dc
monocytesmacrophag
found
low
frequenc
reconstitut
immun
compromis
mice
human
myeloid
cell
among
leucocyt
around
dc
bare
detect
level
granulocyt
one
studi
report
presenc
neutrophil
bone
marrow
frequenc
week
reconstitut
newborn
nodscid
c
mice
group
also
character
delayedtyp
hypersensit
dth
respons
mice
repeat
challeng
trinitrobenzenesulfon
tnb
administr
prior
immun
augment
respons
suggest
exist
intact
innat
adapt
immun
system
involv
macrophag
dendrit
cell
cell
use
keyhol
limpet
hemocyanin
dth
respons
induc
antigen
reconstitut
nodscid
c
mice
cell
macrophag
infiltr
site
inject
swell
could
observ
model
use
parallel
transplant
liver
thymu
hpc
compon
nodscid
c
mice
dth
respons
tetanu
toxoid
collagen
v
could
elicit
swell
influx
human
cell
macrophag
mous
leukocyt
site
inject
furthermor
administr
superantigen
classic
blt
mice
led
mark
increas
cytokin
expans
specif
tcr
cell
upregul
matur
activ
marker
dc
moreov
group
could
prime
antigenspecif
b
cell
respons
vaccin
studi
target
human
dc
nodscid
c
mice
human
immun
system
compon
studi
suggest
function
myeloid
cell
dc
cell
prime
dth
superantigen
driven
immun
reaction
mice
reconstitut
human
immun
system
compon
might
therefor
use
tool
evalu
dc
target
vaccin
candid
recent
describ
human
dc
subset
function
characterist
similar
mous
dc
character
express
also
found
reconstitut
nodscid
c
mice
applic
similar
mous
model
human
immun
system
compon
offer
possibl
valid
immunogen
potenti
dc
subset
vivo
highli
translat
set
mice
human
immun
system
compon
might
allow
test
possibl
role
benefit
cell
type
new
vaccin
strategi
addit
studi
human
innat
immun
compart
mice
human
immun
system
compon
offer
possibl
analyz
infect
pathogen
display
restrict
tropism
human
hematopoet
lineag
adapt
immun
respons
evok
furthermor
introduct
hla
transgen
respect
suscept
mous
strain
might
even
allow
character
human
immun
respons
pathogen
tropism
mous
somat
tissu
epsteinbarr
viru
ebv
infect
human
adult
popul
worldwid
even
though
ebv
infect
cottontop
tamarin
experiment
set
human
known
natur
host
ebv
primari
ebv
infect
remain
asymptomat
especi
adolesc
adulthood
caus
infecti
mononucleosi
furthermor
ebv
infect
associ
develop
variou
malign
includ
burkitt
hodgkin
lymphoma
nasopharyng
carcinoma
lymphoprolif
diseas
ebv
uniqu
abil
immort
b
cell
transform
lymphoblastoid
cell
line
lcl
like
human
herp
virus
ebv
establish
lifelong
latent
infect
mainli
b
cell
within
host
upon
primari
infect
ebvassoci
tumor
express
small
nontransl
viral
encod
rna
includ
ebvencod
rna
eber
subset
latent
ebv
protein
express
pattern
latent
protein
differ
variou
malign
burkitt
lymphoma
exampl
express
nuclear
antigen
ebv
sole
latent
gene
product
express
pattern
refer
latenc
hodgkin
lymphoma
nasopharyng
carcinoma
one
latent
membran
protein
lmp
express
addit
latenc
ii
tumor
aris
immunocompromis
patient
like
hivinfect
individu
transplant
recipi
express
five
addit
ebna
protein
b
c
lp
detect
latenc
iii
three
type
ebv
latenc
also
found
healthi
ebv
carrier
ebv
protein
express
pattern
seem
depend
differenti
stage
infect
b
cell
immun
control
ebv
mainli
mediat
cell
sinc
cellular
subset
human
lymphocyt
poorli
reconstitut
surviv
xenogen
mous
environ
experiment
studi
ebv
immun
control
mice
long
limit
earli
shown
transfer
pbmc
healthi
ebv
carrier
scid
mice
lead
develop
tumor
mani
aspect
resembl
ebv
driven
lymphoprolif
diseas
lpd
howev
poor
surviv
human
cell
within
transfer
pbmc
allow
assess
cell
mediat
immun
control
nevertheless
autolog
ex
vivo
expand
ebv
specif
ctl
home
site
tumor
format
model
specif
kill
infect
tumor
cell
first
mous
strain
allow
direct
ebv
infect
mice
reconstitut
human
immun
cell
nodscid
mous
upon
inject
hpc
human
b
cell
develop
anim
infect
ebv
inject
viru
contain
cultur
supernat
week
infect
mice
show
dissemin
lpd
high
titer
viral
dna
could
detect
peripher
blood
like
ebv
driven
tumor
found
date
mice
human
immun
system
compon
tumor
express
eber
therebi
indic
latenc
iii
residu
mous
nk
cell
activ
nodscid
mice
howev
limit
develop
human
cell
therebi
hamper
attempt
analyz
cell
mediat
immun
control
discuss
addit
knockout
common
nodscid
well
balbc
mice
minim
residu
murin
nk
cell
activ
thu
allow
robust
cell
develop
reconstitut
human
hsc
semin
public
traggiai
et
al
could
show
stabl
human
tcell
homeostasi
balbc
c
mice
reconstitut
human
hpc
cell
expand
upon
ebv
infect
sinc
similar
primari
ebv
infect
human
vast
major
expand
cell
cell
induc
invers
cell
cell
ratio
spleen
cell
isol
infect
mice
produc
stimul
autolog
lcl
therebi
prove
vivo
cell
prime
similar
find
also
report
use
blt
nodscid
c
mice
latter
mous
strain
use
group
other
character
ebv
infect
immun
control
reconstitut
mice
ebv
infect
mice
show
dose
depend
effect
low
dose
infect
raji
infecti
unit
lead
cell
reactiv
lcl
asymptomat
ebv
persist
contrast
intermedi
high
dose
ebv
infect
riu
respect
result
stronger
expans
ebv
specif
cell
especi
high
dose
infect
even
result
ebv
driven
tumor
format
expand
cell
furthermor
show
direct
cytotox
autolog
lcl
ebvepitop
specif
could
identifi
peptid
stimul
among
expand
cell
high
frequenc
hladr
cell
detect
indic
activ
memori
cell
like
phenotyp
research
group
demonstr
observ
prime
ebv
specif
cell
protect
valu
deplet
human
cell
prior
ebv
infect
result
develop
dissemin
lpd
higher
viral
dna
load
spleen
infect
anim
earli
time
point
infect
note
cell
deplet
alon
well
sole
cell
deplet
lead
signific
increas
viral
dna
load
yajima
et
al
report
rapid
onset
lpd
shorter
lifespan
reconstitut
ebv
infect
mice
cell
deplet
confirm
protect
valu
cell
system
howev
human
cell
reconstitut
nodscid
c
c
mice
select
suboptim
condit
mous
thymicepitheli
cell
human
bonemarrow
deriv
cell
murin
thymu
unphysiolog
select
process
includ
select
human
mhc
well
mous
molecul
seem
result
differ
affin
specif
cell
select
allhuman
set
might
explain
detect
cell
specif
mostli
direct
subdomin
ebv
epitop
limit
overcom
introduct
human
hla
transgen
mous
genom
insert
human
heavi
chain
transgen
nodscid
c
mice
mice
immunodomin
peptid
specif
ebv
lytic
latent
antigen
detect
rel
high
frequenc
summari
mice
reconstitut
human
immun
system
compon
model
mani
aspect
ebv
infect
immun
control
also
found
human
ebv
infect
mice
lead
cell
expans
invers
cell
ratio
predomin
activ
memorylik
cell
prime
protect
antivir
cell
respons
dosedepend
manner
prime
cell
recogn
ebv
deriv
epitop
also
found
human
ebv
carrier
higher
viral
dose
ebv
caus
lpd
format
express
latent
ebv
protein
lpd
resembl
tumor
normal
found
immunocompromis
patient
futur
mous
model
reconstitut
human
immun
system
compon
offer
mani
interest
possibl
research
ebv
biolog
immun
control
addit
latenc
pattern
associ
differ
ebv
associ
malign
might
access
mice
certain
infect
condit
exact
requir
could
defin
immun
control
ebv
malign
associ
nontyp
iii
latenc
includ
hodgkin
diseas
burkitt
lmphoma
could
studi
greater
detail
mice
reconstitut
human
immun
system
compon
could
furthermor
serv
model
preclin
drug
test
specif
drug
treatment
ebv
associ
diseas
reli
mainli
inhibitor
viral
dna
polymeras
like
aciclovir
dna
polymeras
inhibitor
effect
reduc
viral
dna
synthesi
lytic
replic
ebv
fail
effect
target
ebv
latent
infect
cell
circumv
problem
one
arm
current
research
focus
develop
small
molecul
target
latent
ebv
protein
like
inhibit
function
mice
human
immun
system
compon
help
test
safeti
efficaci
new
drug
enter
test
primat
even
human
addit
model
might
allow
first
time
assess
vivo
biolog
immun
control
genet
modifi
ebv
strain
variou
modifi
ebv
strain
deriv
artifici
bacteri
chromosom
develop
last
decad
far
effect
target
mutat
delet
specif
ebv
gene
could
address
vitro
would
exampl
modif
viral
lytic
cycl
delet
main
lytic
transactiv
affect
viru
persist
cell
prime
would
loss
immuodomin
protein
like
affect
tumor
develop
immun
surveil
vivo
question
could
address
far
mice
human
immun
system
compon
help
find
answer
question
hope
broaden
understand
complex
interact
ebv
human
bodi
dengu
virusth
four
serotyp
dengu
viru
denv
belong
famili
flavivirida
small
envelop
rna
virus
transmit
mosquito
bite
global
incid
increas
drastic
past
decad
especi
asia
infect
lead
flulik
diseas
call
dengu
fever
df
symptom
rang
mild
sever
includ
fever
rash
headach
nausea
vomit
well
muscl
joint
pain
cellular
basi
contribut
host
immun
system
diseas
understood
detail
case
especi
secondari
infect
anoth
serotyp
patient
develop
dengu
hemorrhag
fever
dhf
thrombocytopenia
plasma
leakag
fatal
date
specif
antivir
treatment
licens
vaccin
avail
partli
due
lack
appropri
anim
model
nonhuman
primat
support
product
infect
show
symptom
df
dhf
sever
mous
model
use
studi
aspect
denv
infect
past
howev
relev
result
human
set
limit
infecti
dose
unphysiolog
high
mice
fulli
immunocompet
furthermor
mousebrainadapt
viru
strain
use
viru
inject
cn
directli
overcom
limit
bent
al
infect
nodscid
mice
reconstitut
cord
blood
cell
denv
serotyp
subcutan
mimic
mosquito
bite
mice
develop
symptom
associ
df
like
increas
bodi
temperatur
rash
thrombocytopenia
mota
ricohess
use
reconstitut
nodscid
c
mice
compar
sever
symptom
induc
differ
strain
denv
serotyp
low
dose
sc
inject
accord
experi
human
target
cell
southeast
asian
strain
virul
one
mous
model
also
strain
induc
product
denvspecif
antibodi
also
reconstitut
c
mice
support
denv
infect
similarli
develop
fever
unlik
reconstitut
nodscid
c
mice
display
sign
rash
hemorrhag
combin
ip
sc
denv
inject
howev
gener
denvspecif
igm
igg
antibodi
part
neutral
capac
also
possibl
gener
denvspecif
cell
respons
reconstitut
mice
jaiswal
et
al
infect
transgen
nodscid
c
mice
reconstitut
posit
hpc
detect
cell
secret
restimul
denv
peptid
pool
conclus
differ
symptom
time
period
immun
respons
denv
report
discuss
like
due
use
differ
mous
model
human
immun
compon
reconstitut
nonetheless
reconstitut
mice
seem
emerg
good
model
studi
pathogenesi
denv
help
discov
therapeut
well
prevent
strategi
hivdespit
effort
infect
human
immunodefci
viru
hiv
result
immunodefici
still
major
threat
global
health
million
peopl
newli
infect
hiv
total
million
peopl
hivposit
worldwid
common
form
transmiss
sexual
intercours
acut
phase
infect
hiv
level
plasma
peak
subsequ
hiv
level
drop
like
due
cell
respons
elimin
infect
cell
major
target
cell
cell
also
monocyt
macrophag
dendrit
cell
infect
latent
phase
infect
human
immun
system
control
viral
infect
result
low
viral
level
plasma
time
cell
level
decreas
caus
immun
system
lose
function
give
rise
opportunist
infect
cancer
develop
eventu
caus
death
combin
antiretrovir
therapi
delay
diseas
progress
cure
vaccin
avail
date
major
problem
pose
integr
viral
dna
host
dna
longterm
viral
persist
high
mutat
rate
viru
facilit
immun
evas
furthermor
lack
suitabl
anim
model
studi
hiv
infect
test
new
antivir
therapeut
vaccin
experi
chimpanze
macaqu
cat
rat
mice
allow
insight
sever
aspect
hiv
biolog
howev
hiv
pathogenesi
model
well
result
immun
respons
differ
human
infect
overcom
problem
sever
mous
model
reconstitut
human
immun
system
compon
test
date
earli
experi
carri
scid
mice
human
fetal
thymu
liver
transplant
scidhu
thyliv
mice
hiv
isol
could
infect
cell
thymocyt
engraft
human
thymu
mice
infect
lead
cell
deplet
therefor
model
allow
vivo
drug
test
studi
viral
cytopathogen
major
limit
lack
complet
immun
system
circul
lymphocyt
human
antigen
present
cell
contrast
cellular
compart
engraft
scid
mice
transplant
human
peripher
blood
mononuclear
cell
scidhupbl
nevertheless
model
mainli
allow
analysi
acut
phase
infect
evalu
antiretrovir
therapi
also
cell
deplet
rapid
cell
replenish
past
year
sever
mous
model
test
hiv
infect
capac
renew
human
cell
compart
reconstitut
human
immun
system
compon
hpc
name
c
nodscid
c
blt
mice
model
support
viral
infect
viremia
plasma
show
dissemin
viru
variou
organ
exhibit
cell
deplet
importantli
reconstitut
mice
mount
least
weak
immun
respons
hiv
sever
group
detect
humor
immun
respons
howev
low
frequenc
exampl
baenzig
et
al
report
one
igg
produc
mous
hiv
infect
reconstitut
c
mice
three
reconstitut
nodscid
c
mice
produc
antibodi
specif
env
gag
mous
background
sato
et
al
found
igg
seven
seven
infect
mice
data
shown
two
part
specif
one
reason
higher
igg
frequenc
studi
might
long
period
time
infect
analysi
also
major
infect
blt
mice
gener
hivspecif
antibodi
epitop
includ
gag
nef
pol
env
prolong
time
period
infect
addit
late
time
point
analysi
human
thymu
blt
mice
might
allow
gener
potent
helper
cell
therebi
frequent
antibodi
respons
respect
cell
compart
cellular
immun
respons
hiv
reconstitut
mice
characterist
featur
report
studi
loss
cell
exampl
infect
hiv
induc
fast
deplet
memori
cell
contrast
effector
memori
cell
preferenti
gradual
lost
hiv
infect
mice
furthermor
posit
regulatori
cell
also
preferenti
deplet
hiv
infect
c
mice
hand
hiv
infect
induc
prolifer
cell
least
reconstitut
nodscid
c
mice
could
mainli
account
increas
memori
cell
blt
mice
sun
et
al
report
activ
well
granzym
perforin
postiv
cell
lymph
node
hiv
infect
accordingli
brainard
et
al
found
signific
increas
activ
hladr
posit
cell
well
perforin
posit
cell
hiv
infect
blt
mice
comparison
uninfect
mice
addit
detect
hivspecif
cell
respons
nine
week
post
infect
well
cell
produc
ex
vivo
peptid
restimul
interestingli
gag
nef
frequent
recogn
cell
antigen
mice
case
human
hiv
infect
patient
despit
robust
immun
respons
also
blt
mice
studi
show
decreas
viral
load
cell
prime
one
possibl
explan
might
emerg
cell
exhaust
chronic
human
infect
hiv
lead
increas
frequenc
express
level
cell
blt
mice
furthermor
posit
correl
percentag
posit
cell
plasma
viremia
support
hypothesi
line
find
blt
mice
reconstitut
nodscid
c
mice
mount
strong
hivspecif
cellular
immun
respons
restimul
gag
deriv
peptid
pool
cell
infect
mice
produc
subset
cell
also
produc
import
cell
respons
underscor
deplet
experi
administr
antibodi
sever
week
infect
mild
effect
viral
load
viremia
significantli
increas
cell
deplet
two
week
infect
studi
mention
mice
infect
hiv
ip
inject
physiolog
way
exposur
sun
et
al
infect
blt
mice
intrarect
abras
rectal
epithelium
like
ip
inject
lead
viral
spread
throughout
bodi
cell
deplet
achiev
intravagin
infect
note
preexposur
prophylaxi
antiretrovir
drug
prevent
vagin
hiv
transmiss
rectal
vagin
transmiss
also
shown
c
mice
could
reproduc
anoth
group
possibl
low
overal
level
reconstitut
particular
mous
background
taken
togeth
newer
mous
model
reconstitut
human
immun
system
compon
recapitul
variou
aspect
hiv
infect
human
even
allow
studi
longterm
chronic
hiv
infect
better
immun
control
might
achiev
improv
reconstitut
transgen
modifi
mice
transgen
express
human
hla
molecul
cytokin
cours
one
keep
mind
variou
cofactor
play
role
aid
progress
studi
tri
address
impair
integr
intestin
barrier
seen
patient
addit
coinfect
pathogen
need
studi
intens
nonetheless
mice
human
immun
system
compon
use
tool
test
antiretrovir
therapeut
possibl
vaccin
howev
import
test
compound
mice
patient
side
side
determin
whether
result
mice
human
immun
system
compon
extrapol
human
set
mice
reconstitut
human
immun
compon
serv
preclin
surrog
model
investig
pathogenesi
viral
infect
human
diseas
model
new
tool
develop
effect
afford
vaccin
therapeut
even
though
past
year
differ
therapeut
vaccin
approach
ebvposit
malign
abl
lead
expans
cell
specif
viral
antigen
studi
far
proven
clinic
effect
hodgkin
lymphoma
nasopharyng
carcinoma
nasopharyng
carcinoma
trial
use
ex
vivo
gener
dc
puls
peptid
deriv
ebv
protein
expans
ebvspecif
cytotox
cell
could
detect
clinic
howev
remiss
slow
tumor
growth
could
observ
data
indic
crucial
test
whether
primari
cell
respons
elicit
vitro
confer
protect
viral
transform
cell
tumor
vivo
ebv
specif
cell
respons
limit
viremia
tumor
format
infect
reconstitut
nodscid
c
mice
particular
mous
model
seem
suitabl
test
vaccin
candid
aim
induc
protect
cell
respons
along
line
test
vaccin
fusion
antibodi
target
endocyt
receptor
human
dendrit
cell
togeth
applic
agonist
adjuv
reconstitut
mice
respons
elicit
cell
respons
well
antibodi
howev
observ
level
cell
reactiv
vaccin
mice
tenfold
lower
level
reactiv
observ
intermedi
dose
ebv
infect
therefor
encourag
result
need
improv
vaccin
mice
challeng
high
dose
ebv
infect
improv
might
includ
select
effici
adjuv
formul
boost
dendrit
cell
matur
effici
cell
prime
antigen
target
lot
attempt
gener
vaccin
fail
despit
year
effort
viru
envelop
evolv
evad
neutral
antibodi
continu
mutat
viru
enabl
evad
antihiv
cell
respons
two
highli
public
hiv
vaccin
trial
prematur
termin
due
high
frequenc
seroconvers
among
vaccin
recipi
indic
noneffect
vaccin
disappoint
result
increas
interest
rodent
model
human
immun
system
compon
hiv
infect
order
test
preclin
vaccin
candid
earlier
studi
use
scidhupbl
mous
model
show
high
dose
neutral
human
monoclon
antibodi
block
viral
entri
therebi
protect
host
develop
high
plasma
viremia
howev
transfer
pbmc
mous
model
sustain
cell
reconstitut
therefor
infect
time
mice
furthermor
suffer
sever
xeno
graft
versu
host
diseas
gvhd
due
high
xenoreacitivi
transplant
human
pbmc
murin
host
cell
c
nodscid
c
blt
mice
contrari
support
longlast
robust
situ
develop
human
hematopoiet
cell
relev
hiv
infect
howev
immun
respons
mice
still
suboptim
humor
adapt
hiv
specif
immun
respons
develop
sever
month
hiv
infect
nevertheless
observ
cell
respons
least
partial
control
viremia
reconstitut
nodscid
c
mice
might
offer
opportun
test
vaccin
candid
least
particular
mous
background
futur
apart
test
potenti
vaccin
candid
ebv
hiv
mice
reconstitut
human
immun
system
compon
also
employ
test
reactiv
elicit
establish
vaccin
new
vaccin
candid
pathogen
mice
human
immun
system
compon
use
test
vaccin
sever
acut
respiratori
syndrom
sar
associ
corona
viru
okada
et
al
transfus
pbmc
healthi
human
volunt
nodscid
c
mice
immun
mice
cdna
construct
encod
structur
antigen
viru
three
immun
candid
vaccin
could
induc
human
neutral
antibodi
respons
modest
cytotox
cell
respons
specif
viru
howev
xenorecognit
mous
host
transfer
pbmc
could
augment
adjuv
activ
vaccin
activ
would
observ
vaccin
human
rapid
alloand
xenorerecognit
mostli
mediat
human
memori
cell
circumv
reactiv
cord
blood
mononuclear
cell
almost
exclus
consist
cell
use
engraft
nodscid
mice
studi
model
exampl
use
test
adenovir
cancer
vaccin
human
carcinoembryon
antigen
cea
camacho
et
al
demonstr
engraft
human
lymphocyt
respond
cancer
vaccin
produc
restimul
vitro
cea
peptid
howev
protect
valu
induc
cell
respons
explor
even
fulli
educ
human
cell
might
rais
xenoreact
immun
respons
toward
mous
host
time
therebi
least
part
contribut
observ
cell
activ
newborn
mice
transplant
human
hpc
develop
human
lymphocyt
toler
mous
tissu
due
select
mous
thymu
therefor
model
might
favour
vaccin
studi
traggiai
et
al
vaccin
reconstitut
balbc
c
mice
tetanu
toxoid
immun
induc
measur
antitetanu
toxoid
igg
antibodi
howev
detect
antibodi
level
significantli
lower
achiev
human
adult
furthermor
recent
studi
show
nodscid
mice
engraft
adult
human
hpc
reconstitut
human
cell
mount
specif
immun
respons
influenza
viru
vaccin
influenza
matrix
protein
cell
expand
mice
vaccin
inactiv
trival
influenza
viru
vaccin
expans
antigenspecif
cell
requir
reconstitut
human
myeloid
compart
nevertheless
protect
valu
vaccin
respons
influenza
viru
infect
investig
studi
taken
togeth
mice
reconstitut
human
immun
system
compon
abl
model
certain
aspect
infect
human
pathogen
specif
immun
control
howev
immun
follow
vaccin
remain
suboptim
potenc
novel
vaccin
candid
especi
trigger
cellmedi
immun
respons
need
improv
protect
valu
vaccin
candid
evalu
subsequ
infect
human
pathogen
advent
new
mous
strain
show
improv
toler
toward
human
immun
system
compon
reconstitut
vivo
human
immun
compart
reconstitut
prolong
period
time
vivo
mous
model
serv
tool
studi
infect
extent
immun
control
human
pathogen
vivo
innat
immun
respons
cell
respons
probabl
model
fairli
well
lack
steadyst
germin
center
format
associ
defect
isotyp
switch
affin
matur
humor
human
immun
respons
probabl
limit
use
new
model
pathogen
requir
antibodi
mediat
neutral
immun
control
howev
model
might
rather
suitabl
studi
pathogen
like
ebv
primarili
control
cell
mediat
immun
furthermor
vaccin
develop
aim
primarili
evalu
antigen
plu
adjuv
candid
improv
cell
immun
might
advanc
mice
pathogen
associ
molecular
pattern
recognit
differ
mous
man
strongli
affect
adjuv
recognit
vaccin
vaccin
studi
might
especi
benefit
new
model
nodscid
c
nsg
nog
nodscid
human
fetal
liver
thymu
organoid
blt
balbc
c
mice
human
immun
system
compon
reconstitut
hematopoiet
progenitor
cell
hpc
use
studi
human
pathogen
infect
immun
control
vaccin
special
emphasi
adjuv
develop
human
immun
system
human
hematopoiesi
therapeut
intervent
human
pathogen
malign
tabl
human
lymphocyt
compart
reconstitut
month
human
fetal
hpc
transfer
mice
